KYZATREX (Testosterone Undecanoate) Patent Expiration, LOE Window & CMS Spending

KYZATREX (Testosterone Undecanoate) by Marius: FDA Orange Book core substance LOE 2041-03-29, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and 4 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMarius
FDA Application & PathwayN213953 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-03-29
Last Listed Patent or Exclusivity Date2041-03-29
Orange Book Patents (*PED Extensions)18 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)4 WAC filings (max 151.6% 2-yr change)